Abstract:BackgroundInterferon (IFN)-α is thought to have a pivotal role in systemic lupus erythematosus (SLE), and type III IFNs (IFN-λ) were recently also associated with SLE. In this study, we measured levels of IFN-α, IFN-λ1, and related cytokines, such as IL-17A, IL-23, and interferon-γ-induced protein 10 (IP-10), in a Karolinska University Hospital cohort of patients with SLE and control subjects. The objective of the study was to investigate if cytokine measurements could identify different subsets of patients with active SLE and higher disease damage.MethodsWe included 261 patients with SLE and 261 population control subjects. All participants underwent a standardized clinical examination. Medical files were reviewed. Patients with SLE were assessed for current organ manifestations, disease activity, and damage. Routine blood parameters, complement levels, and serology were analyzed at the time of inclusion. Levels of IFN-λ1, IFN-α, IL-17A, IL-23, and IP-10 were measured by enzyme-linked immunosorbent assay.ResultsIFN-λ1 and IFN-α were detected in 29% and 44% of patients, respectively, but their levels did not correlate. High serum levels of IFN-λ1 were positively associated with antinucleosome antibodies and lymphopenia but negatively with musculoskeletal damage. Positive correlations between levels of IFN-λ1, IL-17A, and IL-23 were observed. Patients with high levels of these three cytokines had more disease damage, especially renal impairment. High levels of IFN-α were associated with mucocutaneous disease; leukopenia; and low complement, Ro/SSA, and La/SSB. Vascular events and antiphospholipid antibodies were uncommon. We identified two subgroups with high disease activity: one with double-high IFN-λ1 and IFN-α and another with IP-10high. The former had more neuropsychiatric manifestations, and the latter had more arthritis. Increased levels of both types I and III IFNs were found in a proportion of population control subjects. Therefore, high IFN levels do not seem to be SLE-specific biomarkers.ConclusionsMeasurements of circulating IFN-λ1 and IFN-α define subsets of patients with SLE with different characteristics. Levels of IFN-λ1 correlate with T-helper type 17 cytokines and identify a subgroup with more damage. High disease activity is associated with either simultaneous upregulation of IFN-λ1 and IFN-α or independently with IP-10. Our findings could be of major importance when tailoring therapy for patients with SLE with agents targeting IFN pathways.

Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus

B Cell Activation and Plasma Cell Differentiation Are Promoted by IFN-λ in Systemic Lupus Erythematosus

Type I IFN Drives Experimental Systemic Lupus Erythematosus by Distinct Mechanisms in CD4 T Cells and B Cells

IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE)

Type I Interferon Predicts an Alternate Immune System Phenotype in Systemic Lupus Erythematosus

Type I interferons promote the survival and proinflammatory properties of transitional B cells in systemic lupus erythematosus patients

Interleukin-22 From Type 3 Innate Lymphoid Cells Aggravates Lupus Nephritis by Promoting Macrophage Infiltration in Lupus-Prone Mice

The innate immune system in human systemic lupus erythematosus.

Involvement of type Ⅰ interferon in modulating activation and TLRs expression on T cells in systemic lupus erythematosus

Unraveling IFN-I response dynamics and TNF crosstalk in the pathophysiology of systemic lupus erythematosus

Type I interferon in the pathogenesis of systemic lupus erythematosus

LB760 Upregulation of IFI44L Induces Inflammation by Activating TBK1/IRF3 Pathway in Systemic Lupus Erythematosus

Cutting Edge: Intracellular IFN-β and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells

Interferon- regulates abnormally increased expression of RSAD2 in Th17 and Tfh cells in systemic lupus erythematosus patients

Interferon‐α regulates abnormally increased expression of RSAD2 in Th17 and Tfh cells in systemic lupus erythematosus patients

Interferon-λ3/4 genetic variants and interferon-λ3 serum levels are biomarkers of lupus nephritis and disease activity in Taiwanese

Targeting IFN-λ Signaling Promotes Recovery from Central Nervous System Autoimmunity

Type I IFN Protects Against Murine Lupus

Type I Interferon Inhibition of MicroRNA‐146a Maturation Through Up‐Regulation of Monocyte Chemotactic Protein–Induced Protein 1 in Systemic Lupus Erythematosus

Higher Activation of the Interferon-Gamma Signaling Pathway in Systemic Lupus Erythematosus Patients with a High Type I IFN Score: Relation to Disease Activity

Uncoupling interferons and the interferon signature explains clinical and transcriptional subsets in SLE